Stocktoria
Amphastar Pharmaceuticals, Inc. AMPH
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-06-25
Amphastar Pharmaceuticals, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 49.5% | 51.1% | 54.5% | 49.9% | 45.6% |
| Operating margin | 19.5% | 28.1% | 30.6% | 21.5% | 16.0% |
| Net margin | 13.6% | 21.8% | 21.3% | 18.3% | 14.2% |
| FCF margin | 16.8% | 23.5% | 22.6% | 13.1% | 16.1% |
| Return on assets | 6.0% | 10.1% | 9.1% | 12.3% | 9.2% |
| Return on equity | 12.4% | 21.8% | 21.5% | 17.3% | 13.9% |
| Debt / equity | 0.79× | 0.84× | 0.94× | 0.14× | 0.18× |
| Current ratio | 4.02 | 3.07 | 2.17 | 3.99 | 3.06 |
| Revenue growth | -1.7% | 13.6% | 29.1% | 14.0% | 25.1% |
Source: SEC EDGAR filings · CIK 0001297184 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.